Showing 1901-1910 of 2105 results for "".
- Blarcamesine Reduces Rett Syndrome Symptomshttps://practicalneurology.com/news/blarcamesine-reduces-rett-syndrome-symptoms/2469814/Blarcamesine (Anavex2-73; Anavex Life Sciences Corp, New York, NY), once daily oral liquid doses of up to 30mg, demonstrated statistically significant reductions in Rett syndrome symptoms with related changes in potential biomarkers, GABA and L-Alpha-aminoadipic acid (L-AAA), of disease pathology
- Tic Development Not Associated With Strep in Children of Parents With Chronic Tic Disordershttps://practicalneurology.com/news/tics-development/2469813/A study published in Neurology found there was no link between a strep throat infection and the development of tics in children who have a parent or sibling with a chronic tic disorder. In the study, 24% of the children (n=61) developed tics. At 2-year follow up assessments, 7 more chil
- Byrostatin Improves Cognition in Advanced Alzheimer Diseasehttps://practicalneurology.com/news/byrostatin-improves-cognition-in-advanced-alzheimer-disease/2469812/An article published in the Journal of Alzheimer Disease provides evidence from 2 placebo-controlled trials that bryostatin (DB11752; Synaptogenix Inc., New York, NY) improved cognition from baseline in individuals with advanced Alzheimer disea
- A New Phase 2 Trial of Tominersen for Early Huntington Disease Designedhttps://practicalneurology.com/news/a-new-phase-2-trial-of-tominersen-for-early-huntington-disease-designed/2469801/A new phase 2 trial is planned to evaluate tominersen (IONIS-HTTRx; Ionis Pharmaceuticals, Carlsbad, CA) to treat early-stage Huntington disease (HD). Although the phase 3 GENERATION HD1 trial of tominersen for HD was halted, post hoc analyses suggest tominersen may benefit younger adults with lo
- First Participant Enrolls in Clinical Trial of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolls-in-clinical-trial-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469799/The twin phase 3 clinical trials ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) enrolled the first participant for potential trea
- First Participant Dosed of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/first-participant-dosed-of-novel-chimeric-cell-therapy-for-duchenne-muscular-dystrophy/2469789/The first patient has been treated in a phase 1 clinical study of dystrophin-expressing chimeric cells (DEC)(DT-DEC01; Dystrogen Therapeutics, Miami, FL) for the treatment of Duchenne muscular dystrophy (DMD). The first participant, age 6 years, received an infusion of DEC, tolerated th
- Diagnostic Delay for Focal Epilepsy Is Significantly Longer in Children and Adolescentshttps://practicalneurology.com/news/diagnostic-delay-for-focal-epilepsy-is-significantly-longer-in-children-and-adolescents/2469768/Retrospective analysis of data from the Human Epilepsy Project, showed time to diagnosis of epilepsy in people with focal seizure onset before vs after age 18 years was a median 340 vs 207 days (P=.012). For those who had only nonmotor focal seizures, the mean time to diagnosis was 1,019
- Evidence of Utility of Gene Testing for Children with Unexplained Epilepsy Continues to Growhttps://practicalneurology.com/news/evidence-of-utility-of-gene-testing-for-children-with-unexplained-epilepsy-continues-to-grow/2469767/Analysis of 152 children with unexplained epilepsy treated at a single institution had care that was substantially affected by genetic evaluation, suggesting any child with unexplained epilepsy should have such an evaluation. Of those tested, 72% had changes in medical care in at
- First Participant Enrolled in Phase 3 Study of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolled-in-phase-3-study-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469761/The first participant has enrolled in the phase 3 ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) for potential treatment of relapsing m
- FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatmenthttps://practicalneurology.com/news/fda-accepts-investigational-new-drug-application-and-grants-fast-track-designation-of-trehalose-for-spinocerebellar-ataxia-treatment/2469747/The Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application to trehalose (SLS-005; Seelos Therapeutics, New York, NY) for spinocerebellar ataxia (SCA) treatment. The FDA has granted the program Fast Track designation for SCA, and trehalose has previously rec